Author

F. Beca

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access 2026

TROFUSE-032: a phase 3, randomized study of pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer or hr+/her2– breast cancer

Introduction: Trophoblast cell surface antigen 2 (TROP2) is highly expressed in triple-negative breast cancer (TNBC) and is associated with poor prognosis. Current standard of care for high-risk, early-stage TNBC is neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab after surgery. The same a...

R. Freitas-Júnior, P. Schmid, Jing Wei et al. · Mastology · 0 citations

Open access Oct 2026

TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.

CLINICAL TRIAL REGISTRATION NCT06966700 (ClinicalTrials.gov); EU CT 2024-520190-12 (EudraCT).

P. Schmid, Javier Cortés, R. Hui et al. · Future Oncology · 0 citations